Navigation Links
Cambrex to Present at UBS 22nd Annual Global Healthcare Services Conference
Date:2/6/2012

EAST RUTHERFORD, N.J., Feb. 6, 2012 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce that Greg Sargen, Executive Vice President and Chief Financial Officer, will make a presentation on the Company at the UBS 22nd Annual Global Healthcare Services Conference on February 8, 2012 at 10:00 AM EST at the Grand Hyatt New York, New York City.

The slide presentation can be accessed from the Cambrex website http://www.cambrex.com in the Investors section of the website under Webcasts & Presentations.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.  


'/>"/>
SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cambrex Reports Third Quarter 2011 Results
2. Cambrex to Announce Third Quarter 2011 Financial Results on November 3, 2011
3. Cambrex to Announce Second Quarter 2011 Financial Results on August 2, 2011
4. Cambrex Reports First Quarter of 2011 Results
5. Cambrex Reports Fourth Quarter and Full Year 2010 Results
6. Cambrex to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
7. Cambrex Zenara Manufacturing Facility Receives European GMP Approval
8. Shawn P. Cavanagh Appointed Chief Operating Officer of Cambrex
9. Cambrex Zenara Supplies Product for Launch of Nicorette® in India
10. Cambrex Acquires Stake in Zenara Pharma
11. Cambrex to Announce Third Quarter 2010 Financial Results on November 3, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 21, 2014 McCord Research, Inc. was ... No. 8,796,315). This patent describes a method for ... to the inventor, Dr. McCord, this method includes ... healing, a composition of an effective amount of ... cord blood, such that the administration of the ...
(Date:7/21/2014)... /PRNewswire-iReach/ -- Nitrosolution.com, a website that features safe and ... first anniversary in August. The online retailer specializes in ... body,s ability to produce nitric oxide. Called Nitroxyl, it ... a variety of phytonutrients and other natural ingredients that ... nitric oxide production in the arteries and ...
(Date:7/21/2014)...  Champions Oncology (OTC: CSBR), a company engaged in ... personalize the development and use of oncology drugs, today ... for the fourth quarter and fiscal year ended April ... close. The company will host a conference ... p.m. EDT (1:30 p.m. PDT). To participate in the ...
Breaking Medicine Technology:US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2
... Feb. 8, 2011 DURECT Corporation (Nasdaq: ... has launched commercial sales of its Food and Drug ... injectable animal health drug utilizing DURECT,s SABER™ technology to ... on net sales of SucroMate and will supply one ...
... DIEGO, Feb. 8, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... the 13th Annual Bio CEO & Investor Conference on Tuesday, ...  The conference is being held at the Waldorf-Astoria Hotel in ... Officer of Anadys, will provide an overview of Anadys and ...
Cached Medicine Technology:DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 2DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 3Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference 2
(Date:7/21/2014)... for Public Affairs Research has released the results of ... it means to be a quality health care provider ... Robert Wood Johnson Foundation, sheds new light on how ... and doctors, as well as the information they use ... produces new and actionable data during a crucial period ...
(Date:7/21/2014)... Western University of Health Sciences ... For” by the Chronicle of Higher Education for ... Honor Roll for the first time. , WesternU ... and Benefits, Confidence in Senior Leadership, Job Satisfaction, ... “Western University of Health Sciences is a great ...
(Date:7/21/2014)... -- Good parenting and life skills coaching seem ... a new study suggests. Inflammation is a ... to a number of illnesses, according to Northwestern ... childhood and adulthood involve excessive inflammation. The process ... and some cancers," study author Gregory Miller, a ...
(Date:7/21/2014)... A new study suggests that potential help in ... your refrigerator. The study found that regular intake ... or supplements, may help ease the condition. Researchers ... between probiotics and blood pressure. The studies involved a ... blood pressure. People who consumed probiotics had an ...
(Date:7/21/2014)... may be getting women to go to the hospital more ... shows women have longer hospital stays and are more likely ... attack. , In the study published online today in the ... from Yale School of Medicine analyzed 230,684 hospitalizations for heart ... of 1.1 million hospitalizations reported in a national database from ...
Breaking Medicine News(10 mins):Health News:National survey from AP-NORC examines perceptions of health care provider quality 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Life Skills, Parenting Classes May Cut Inflammation in Poor Kids 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
... to Cover Medical Devices, ARLINGTON, Va., Nov. 2 ... Capital Markets) today announced that,Christopher Warren has joined FBR ... Analyst within its healthcare group and will,focus on the ... of experience in equity research, and we,value the disciplined, ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ) announced ... offer convertible senior notes. The decision not to ... due principally to prevailing,market conditions resulting in note ... Note Regarding Forward-Looking Statements This release contains ...
... Pa., Nov. 2 Kensey Nash Corporation,(Nasdaq: ... licensed U.S. patent,6,175,669, Optical Coherence Domain Reflectometry Guidewire, ... the intellectual,property portfolio related to its chronic total ... enhanced optical sensing capabilities,allowing it to sense locations, ...
... Just how much of the time,that sales people should be ... internal communication? Pharmaceutical sales directors agree the answer is ... for internal communication - or 6 weeks per rep,per year ... year,according to a recent research study by Best Practices, LLC. ...
... inhibitor demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, ... the results of a 14-day Phase 1 multiple ascending,dose monotherapy study ... study, being presented as a "late-breaker" abstract at,the 58th Annual Meeting ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) will announce ... 8, 2007, after market close. The announcement ... followed by a conference call and live webcast ... 4:30 p.m. Eastern. Interested parties may access the,live ...
Cached Medicine News:Health News:FBR Capital Markets Hires Senior Healthcare Analyst 2Health News:Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5Health News:Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results 2
... Apron has standard front protection. ... from the shoulders to the ... a 6" wide elastic belt. ... apron snug. Belts may be ...
... new Breast Overlay Apron ... provide extra coverage for ... adjustable velcro flaps allow ... fit, plust added coverage ...
Lap pad used to protect pelvic regions...
... necessary, the Two-Piece should be your ... comfort through more efficient distribution of ... vest comes with shoulder pads and ... well as an attached belt to ...
Medicine Products: